| abstract |
The present invention provides anti-CLL1 antibodies and applications thereof, wherein the variable regions of the anti-CLL1 antibodies include SEQ ID NOs: 1-6, SEQ ID NO: 5 and SEQ ID NOs: 7-11 or SEQ ID NOs: 12-17 CDRs. The anti-CLL1 antibody of the present invention has significant binding ability to both free and cell surface CLL1, and after humanization transformation, the affinity of the antibody to CLL1 is further improved, and has important application prospects in the clinical diagnosis and/or treatment of tumors . |